Fas and FasL gene polymorphisms are not associated with cervical cancer but differ among Black and Mixed-ancestry South Africans

BMC Research Notes

Volumn 2, Issue , 2009, Pages

  Chatterjee, Koushik ^a   Engelmark, Malin ^b   Gyllensten, Ulf ^b   Dandara, Collet ^c   Merwe, Lize ^d,e   Galal, Ushma ^d   Hoffman, Margaret ^a   Williamson, Anna Lise ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^e UNIVERSITY OF THE WESTERN CAPE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 77149154679     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-2-238     Document Type: Article

References (29)

1. Gene discovery in cervical cancer : towards diagnostic and therapeutic biomarkers. Martin CM Kehoe L, Spillane CO O'Leary JJ, Mol Diagn Ther 2007 11 277 290 17963416
2. Apoptotic cell death in the pathogenesis of infectious diseases. Dockrell DH, J Infect 2001 42 227 234 10.1053/jinf.2001.0836 11545564
3. Activation-induced cell death in T cells and autoimmunity. Zhang J Xu X Liu Y, Cell Mol Immunol 2004 1 186 192 16219166
4. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Huang QR Morris D Manolios N, Mol Immunol 1997 34 577 582 10.1016/S0161-5890(97)00081-3 9393960
5. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Sibley K Rollinson S, Allan JM Smith AG, Law GR Roddam PL, et al. Cancer Res 2003 63 4327 4330 12907599
6. A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. Kanemitsu S Ihara K, Saifddin A Otsuka T, Takeuchi T Nagayama J, et al. J Rheumatol 2002 29 1183 1188 12064832
7. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. Wu J Metz C, Xu X Abe R, Gibson AW Edberg JC, et al. J Immunol 2003 170 132 138 12496392
8. Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Lai HC Sytwu HK, Sun CA Yu MH, Yu CP Liu HS, et al. Int J Cancer 2003 103 221 225 10.1002/ijc.10800 12455036
9. Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: An analysis of haplotype and gene-gene interaction. Lai HC Lin WY, Lin YW Chang CC, Yu MH Chen CC, et al. Gynecol Oncol 2005 99 113 118 10.1016/j.ygyno.2005.05.010 15996722
10. Evaluation of Fas gene promoter polymorphism in cervical cancer patients. Dybikowska A Sliwinski W, Emerich J Podhajska AJ, Int J Mol Med 2004 14 475 478 15289903
11. No evidence of the involvement of the Fas -670 promoter polymorphism in cervical cancer in situ. Engelmark MT Renkema KY Gyllensten UB, Int J Cancer 2004 112 1084 1085 10.1002/ijc.20515 15316939
12. FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. Sun T Zhou Y, Li H Han X, Shi Y Wang L, et al. J Exp Med 2005 202 967 974 10.1084/jem.20050707 16186185
13. Variants of chemokine receptor 2 and interleukin 4 receptor, but not interleukin 10 or Fas ligand, increase risk of cervical cancer. Ivansson EL Gustavsson IM, Magnusson JJ Steiner LL, Magnusson PK Erlich HA, et al. Int J Cancer 2007 121 2451 2457 10.1002/ijc.22989 17688234
14. Cancer in twins: genetic and nongenetic familial risk factors. Ahlbom A Lichtenstein P, Malmstrom H Feychting M, Hemminki K Pedersen NL, J Natl Cancer Inst 1997 89 287 293 10.1093/jnci/89.4.287 9048832
15. Familial risks in cervical cancer: is there a hereditary component? Hemminki K Dong C Vaittinen P, Int J Cancer 1999 82 775 781 10.1002/(SICI)1097- 0215(19990909)82:6<775::AID-IJC1>3.0.CO;2-V 10446440
16. Genetic link to cervical tumours. Magnusson PK Sparen P Gyllensten UB, Nature 1999 400 29 30 10.1038/21801 10403244
17. Risk of invasive cancer of the cervix in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen oral contraceptives (South Africa). Shapiro S Rosenberg L, Hoffman M Kelly JP, Cooper DD Carrara H, et al. Cancer Causes Control 2003 14 485 495 10.1023/A: 1024910808307 12946044
18. Limited Pap screening associated with reduced risk of cervical cancer in South Africa. Hoffman M Cooper D, Carrara H Rosenberg L, Kelly J Stander I, et al. Int J Epidemiol 2003 32 573 577 10.1093/ije/dyg081 12913031
19. Analysis of the entire HLA region in susceptibility for cervical cancer: a comprehensive study. Zoodsma M Nolte IM, Schipper M Oosterom E, van der SG de Vries EG, et al. J Med Genet 2005 42 49 10.1136/jmg.2005.031351 16061555
20. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Schaid DJ Rowland CM Tines DE Jacobson RM, Poland GA, Am J Hum Genet 2002 70 425 434 10.1086/338688 11791212
21. Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. Davidson WF Giese T Fredrickson TN, J Exp Med 1998 187 1825 1838 10.1084/jem.187.11.1825 9607923
22. Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma, and Hodgkin's disease. Peters AM Kohfink B, Martin H Griesinger F, Wormann B Gahr M, et al. Exp Hematol 1999 27 868 874 10.1016/S0301-472X(99)00033-8 10340403
23. Alterations of Fas (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder. Lee SH Shin MS, Park WS Kim SY, Dong SM Pi JH, et al. Cancer Res 1999 59 3068 3072 10397246
24. Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Lee SH Shin MS, Park WS Kim SY, Kim HS Han JY, et al. Oncogene 1999 18 3754 3760 10.1038/sj.onc.1202769 10391683
25. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Takahashi T Tanaka M, Brannan CI Jenkins NA, Copeland NG Suda T, et al. Cell 1994 76 969 976 10.1016/0092-8674(94)90375-1 7511063
26. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. Sun T Miao X, Zhang X Tan W, Xiong P Lin D, J Natl Cancer Inst 2004 96 1030 1036 15240787
27. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. Zhang X Miao X, Sun T Tan W, Qu S Xiong P, et al. J Med Genet 2005 42 479 484 10.1136/jmg.2004.030106 15937082
28. An examination of the Apo-1/Fas promoter Mva I polymorphism in Japanese patients with multiple sclerosis. Niino M Kikuchi S, Fukazawa T Miyagishi R, Yabe I Tashiro K, BMC Neurol 2002 2 8 10.1186/1471-2377-2-8 12188927
29. Evaluation of a Apo-1/Fas promoter polymorphism in Korean stroke patients. Seo JC Han SW, Yin CS Koh HK, Kim CH Kim EH, , et al. Exp Mol Med 2002 34 294 298 12515395